Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;51(2):283-298.
doi: 10.1016/j.gtc.2021.12.005. Epub 2022 Apr 22.

Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Chung Sang Tse  1 , Parambir S Dulai  2
Affiliations
Review

Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Chung Sang Tse et al. Gastroenterol Clin North Am. 2022 Jun.

Abstract

Over the past 2 decades, there have been incredible advances in the pharmacotherapeutic options for the treatment of patients with moderately to severely active Crohn's disease. Despite the leaps and strides in safety, efficacy, and mechanistic specificity of treatment targets, a significant portion (up to ∼20-50%) of patients have refractory Crohn's disease ± concomitant rheumatologic disease/extraintestinal manifestations for which existing biologic and small molecule therapies are ineffective. In this review, we will explore the available evidence for the use of dual advanced therapies (combination of biologic and/or small molecule therapies) and novel pharmacotherapies in phase 2 to 3 clinical trials.

Keywords: Clinical trials; Combination biologics and small molecules; Dual biologic therapies.

PubMed Disclaimer

Conflict of interest statement

Disclosure P.S. Dulai: Consulting and/or grant support from Takeda, Abbvie, Janssen, Pfizer, Gilead, BMS, Lily, Novartis, Scipher, and Prometheus. C.S. Tse has nothing to disclose.

Publication types

MeSH terms